#SectorSpotlight: The FDA has approved sunvozertinib, bringing a long-awaited targeted therapy to underserved patients with EGFR exon 20 insertion–positive metastatic NSCLC with limited treatment options. As a global #OncologyCRO with deep experience in NSCLC and other solid

Neuroscience research moves fast, so should your CRO. From rare neuro disorders to psychiatric and neuromuscular diseases, TFS brings precision, speed, and global reach to every trial. Whether you’re tackling early-phase complexity or scaling global studies, our #NeuroscienceCRO

Fresh ideas fuel progress #AtTFS. This summer, we're spotlighting new voices like Ibrahim, whose energy and curiosity help drive meaningful change. See what inspires him and how you could be next. Learn more at tfscro.com/careers/ #TogetherWeMakeADifference

Need specialized support to meet tight study timelines? Strategic Resourcing Solutions #AtTFS delivers global expertise fast, matched to your protocol, site needs, and milestones. Contact us to keep your trial moving: bit.ly/4ceXJd7 #ClinicalCRO

TFS is launching our #OutOfOffice series spotlighting how our teams rest, recharge, and celebrate together. Because we know the best work starts with time well spent off the clock. #AtTFS, we champion a culture where stepping away is part of showing up strong. You can join us!

Smarter design isn’t optional in rare neuro trials; it’s essential. Learn how natural history and external controls, executed with TFS expertise, can drive success. Read Dr. Wasti's insights: bit.ly/3UmD937 #NeuroscienceCRO

This #WorldBrainDay, we recognize the human stories behind every trial and diagnosis. See how our #NeuroscienceCRO is driving progress through science and empathy: bit.ly/3IwBl4X #TogetherWeMakeADifference

We’re proud to celebrate another milestone, enrolling 900+ subjects in a global DME study across the US, Europe, AsiaPac, and beyond, ahead of schedule! This milestone reflects the strength of our global site relationships and our shared commitment to accelerating access to

Facing tight timelines in ophthalmology trials? See how TFS delivered a time-sensitive Phase III dry eye disease study on time and without compromising quality. As a trusted #OphthalmologyCRO, TFS helped the sponsor stay on track, hit key milestones, and advance their dry eye

Our #OutOfOffice series continues, this time with our Marketing & Events Specialist, Miranda, who traded calendars and campaigns for coastlines and cappuccinos on a recent trip to Italy. #AtTFS, we support our teams in stepping away when they need to recharge. Because when our

This #WorldHepatitisDay, we’re amplifying the call to accelerate research in infectious and inflammatory diseases that impact millions worldwide. Explore how our #InternalMedicineCRO is driving smarter trials in high-need indications: bit.ly/4hsvJ8q

With deep expertise in internal medicine and neuroscience, Dr. Wasti continues to contribute to impactful global health research, this time helping explore a promising TB vaccine candidate. In this peer-reviewed publication, Dr. Wasti and his co-authors conducted a systematic

The FDA’s draft guidance on including pregnant and breastfeeding women in #ClinicalTrials is a turning point for research equity, bringing us closer to safer, evidence-based care for all. As a global mid-sized CRO with deep expertise across key therapeutic areas, we welcome this

From preclinical to post-approval, #AtTFS our Strategic Resourcing Services help sponsors secure critical expertise without disrupting timelines. Need a hard-to-fill role fast? Learn how TFS can help rewrite the story: bit.ly/4ks5dxS.

Next up in our #OutOfOffice series is Tabitha, Business Development Director #AtTFS, who recently took time to explore London with her family, trading meetings for museums and reconnecting beyond the screen. Here’s to well-timed breaks and the people who make them meaningful.

The FDA has approved Dupixent as the first and only targeted therapy for adult bullous pemphigoid, a major step forward in treating rare inflammatory skin diseases. Learn more: bit.ly/4l8ZwnC #AtTFS, we bring proven expertise to #dermatology and #immunologic trials,

The future of atopic dermatitis treatment is here, and it’s changing how trials are designed. Our latest white paper breaks down the science. Explore emerging therapies, biomarker-driven strategies, and trial design shifts shaping AD research in 2025. Developed by our

We're heading home this October for Nordic Life Science Days & OCT Nordics. As a global, full-service CRO headquartered in Lund, we're proud to participate in these leading Nordic events. From biotech innovation to clinical outsourcing strategy, these conferences spotlight what

Enrollment races. Evolving regulations. Rising complexity. Clinical trials in 2025 are higher stakes than ever. Our latest blog explores how sponsors can stay ahead with strategies built for today’s realities. From early-stage planning and fit-for-purpose tech to proactive risk

Gene therapy is gaining ground in dermatology. New research points to viral and non-viral vectors, gene editing, and RNA approaches with potential to change how we treat a range of skin conditions. bit.ly/45TG3Dc From epidermolysis bullosa to chronic wounds, the science